Ipravent Rotacaps contain Ipratropium bromide 40 mcg per dose, a bronchodilator used primarily in the management of chronic obstructive pulmonary disease (COPD) and asthma. Ipratropium is an anticholinergic agent that works by inhibiting the action of acetylcholine on muscarinic receptors in the airway smooth muscle, leading to bronchodilation and relief of bronchospasm. It is administered via inhalation using a rotahaler device, allowing direct delivery to the respiratory tract, which enhances its therapeutic effect while minimizing systemic exposure. Ipravent Rotacaps are indicated for maintenance treatment to improve lung function and reduce symptoms such as wheezing, shortness of breath, and coughing associated with obstructive airway diseases. Onset of action typically occurs within 15 minutes, with a duration of effect lasting up to 6 hours, making it suitable for regular use throughout the day. The medication is generally well tolerated; however, common adverse effects may include dry mouth, cough, and throat irritation. Ipravent Rotacaps should be used with caution in patients with hypersensitivity to atropine derivatives and those with narrow-angle glaucoma or urinary retention. It is essential to follow prescribed dosing and consult a healthcare professional for appropriate use and monitoring.